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Introduction 
 
Glycaemic control (GC) to improve outcomes in critical care has proven difficult, yielding significant glycaemic variability and hypoglycaemia. The strong association of 
glycaemia, glycaemic variability and mortality are due either to patient-condition (non-survivors are harder to control) or difference in control (non-survivors and survivors 
are equally difficult to control). This study uses a clinically validated and patient-specific insulin sensitivity (SI) level to compare metabolic variability (difficulty to control) in 
survivors and non-survivors with equivalent glycaemic control.  Specifically, are non-survivors more variable and thus harder to control?  
Methods 
Clinical data: 
Retrospective data from 145 patients who underwent at least 24 hours of insulin 
therapy on the SPRINT glycaemic controller, starting within 12 hours of ICU 
admission at the Christchurch Hospital ICU, is used. Demographics of this cohort are 













Table 1 – Demographic details of 145 patients cohort. Patients started SPRINT within 12 hours of ICU admission and underwent at 
least 24 hours of GC. 
 
Metrics: 
Insulin sensitivity (SI) is hourly identified from clinical BG and insulin data, based on 
a clinically validated model found in [1]. SI variability (%ΔSI) is defined as the hour-
to-hour percentage change in SI: 
 
 
Analysis and Statistics: 
SI and %ΔSI and their evolution are analysed in 6-hour blocks over the first 72 hours 
of GC, comparing them for survivors and non-survivors.  
• Hypothesis testing is used to examine difference between cohorts. If the 
bootstrapped 95% CI in median SI difference or median %ΔSI does not cross 
zero, the difference is considered significant (p ≤ 0.05). The Kolmogorov-
Smirnov test compares bias and shape in %ΔSI and is considered significant if 
p ≤ 0.05. 
• Equivalence testing is used to assess if any differences are meaningful. The 
equivalence range is define as the change in SI required to exceed ±9,4%   [2] 
BG measurement error reported for the device used. Typically ≈12-15%, but is 














Table 2 shows median SI [IQR] for survivors and non-survivors over first 72 hrs.  
Figures 1 and 2 shows the SI and %ΔSI cdfs using 6 hrs blocks and Figure 3 shows 
the equivalence test for SI (left) and %ΔSI  (right). Key results include: 
  Cohort 1 Survivors Non-Survivors P 
N 145 119 (82%) 26 (18%) / 
Age (Yr) 67 [57 75] 66 [57 74] 73 [59 78] 0.15 
Gender (M/F) 91/54 75/44 16/10 1.0 
APACHE II Score 20 [17 26.25] 19 [16 25] 22 [19 31] <0.01 
ICU Length of Stay (hrs) 113 [65 212] 127 [65 256] 108 [65 154] 0.49 
Diabetic type I/ type II 
(total) 
9 / 24 (33) 8 / 21 (29) 1 / 3 (4) 1.0 
Median BG [IQR] mmol/L 5.7 [4.9 6.7] 5.8 [5.0 6.8] 5.5 [4.8 6.4] 0.03 
% BG in 4.4-8 mmol/L 
[IQR] 
79.3 79.1 80.0 0.71 
Number patients BG < 2.2 0 0 0 / 
Median Insulin [IQR] U/hr 3 [2 4] 3 [2 4] 3 [1 3] <0.01 
Median feed [IQR] g/hr 3.25 [1.92 4.87] 3.25 [1.92 4.87] 3.25 [1.92 4.87] 0.70 
Hours 





 0-5 1.39 [0.50 2.54] 1.64 [0.63 2.63] -0.25 [-0.60, 0.06] 0.67 -8.12 [-16.22, 4.67] 
6-11 1.94 [1.11 3.35] 2.58 [1.42 3.97] -0.63 [-1.04, -0.11]* 0.53 -1.31 [-6.22, 5.74] 
12-17 2.54 [1.42 4.48] 3.39 [1.63 4.79] -0.79 [-1.46, 0.22] 0.62 -0.98 [-9.46, 7.26] 




 24-29 2.96 [1.65 4.98] 3.30 [1.81 4.85] -0.30 [-0.73, 0.13] 0.30 -2.70 [-8.60, 3.29] 
30-35 3.08 [1.83  5.73] 4.34 [2.35 7.21] -1.23 [-2.16, -0.20]* 0.78 0.34 [-8.54, 6.75] 
36-41 3.13 [1.81 5.44] 3.42 [2.23 5.36] -0.29 [-1.01, 0.43] < 0.05 6.10 [0.35, 10.70]* 




 48-53 3.28 [1.95 5.36] 4.83 [3.13 8.63] -1.57 [-2.36, -0.97]* 0.30 -2.12 [-7.41, 1.77] 
54-59 3.55 [2.03 5.50] 4.65 [2.53 7.27] -1.12 [-2.04, -0.40]* 0.35 3.37 [-1.77, 8.20] 
60-65 3.39 [2.18 5.18] 4.19 [2.71 6.83] -0.81 [-1.59, -0.01]* 0.45 -2.50 [-9.06, 3.35] 
66-71 3.40 [2.43 5.07] 3.86 [2.43 8.30] -0.47 [-1.43, 0.16] 0.35 -2.76 [-8.66, 2.80] 
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Conclusion 
 
Patient-specific SI and %ΔSI metrics are used to assess controllability between 
survivors and non-survivors. While SI level tends to determine the total amount of 
insulin to be titrated, it is variability that determines the risks of insulin therapy and 
overall controllability (hyper- and hypo- glycaemia). 
 
Overall, similar to higher SI for non-survivors and equivalent variability suggest 
survivors and non-survivors are equally controllable given an effective glycaemic 
control protocol. 
 
This outcome suggests that glycaemic level and variability, and thus the 
association between glycaemia and outcome, is essentially determined by the 
quality of glycaemic control, and not the underlying patient variability. 
• SI level is not equivalent and is often not statistically different between 
survivors and non-survivors. 
• SI level is higher in non-survivors than survivors, and this result is often 
statistically significant as glycaemic control progresses. 
• SI variability is equivalent between survivors and non-survivors, and not 
statistically different for all but two 6-hour blocks. 
Figure 1 – SI level cdfs for survivors (blue) and non-survivors (red). Solid lines represent the first 6 hour block and dashed line the 
second. 
Figure 3 – Equivalence testing on SI (left) and %ΔSI (right). The solid lines give equivalence range for 9.4% BG error and the dotted 
lines a smaller 7% error reported for the device used [2, 3]. 
 
Table 2 – Survivor and non-survivors median SI [IQR] and 95% CI of median SI difference interval. KS-test performance on %ΔSI and 
95% CI median of difference in median %ΔSI is also shown. 95% CI marked with (*) are considered significant.  SI is analysed in first 3 
columns and %ΔSI in last 2 columns 
Figure 2 –%ΔSI cdfs for survivors (blue) and non-survivors (red). Solid lines represent the first 6 hour block and dashed line the 
second. 
